**Imprime PGG: A Novel Innate Immune Activator**

In preclinical tumor models, Imprime PGG enhances the efficacy of CPI monotherapy. Imprime PGG is a novel, IV administered Dectin-1 agonist, which promotes a shift from the immunosuppressive "M2" state to a polarized "M1" state. This immune activation is the "active" drug, promoting shift from immunosuppressive "M2" state to a polarized "M1" state. This immune activation is the "active" drug, promoting shift from immunosuppressive "M2" state to a polarized "M1" state.

**IMPRIME 1 (NCT02981303) Study Design**

- **1° endpoint - ORR by RECIST v1.1 and safety.**
- Imprime PGG administered by IV infusion 4mg/kg, weekly for 24 weeks.
- ECOG status 0-1
- ≥ 1 prior line of chemotherapy after the diagnosis of metastatic TNBC (mTNBC)

**IMPRIME 1 Kaplan-Meier Overall Survival Plot**

- Best Overall Response and Reason for Discontinuation
- 1. Imprime PGG in combination with pembrolizumab shows promising clinical benefit in previously treated, metastatic TNBC patients.
- Across multiple clinical efficacy measures
  - Overall Survival
  - Overall Response Rate (ORR)
  - Clinical benefit in previously-treated, metastatic TNBC patients

**IMPRIME 1 5.21 Open label, multicenter Ph 2 study combining Imprime PGG with pembrolizumab (pembrolizumab) in previously-treated, metastatic Triple Negative Breast Cancer (mTNBC)**

- O'Day S.J., Burgess V.F., Chmielowski B. et al.

- 2. Imprime PGG-mediated innate immune activation requires Anti Beta Glucan Antibody (ABA)
- Imprime PGG reprograms the immunosuppressive tumor microenvironment and activates antigen presenting cells (APCs).

**IMPRIME 1 Efficacy Data**

- Table 2. Patient Populations and ORR

**IMPRIME 1 Safety Data**

- Table 3. mTNBC Patients with Prior Hormone Therapy

**IMPRIME 1 Translational Research**

- Peripheral Blood Analyses

**IMPRIME 1 Tumor Biopsy Analyses: Liver Metastasis**

- Pre-Treatment vs On-Treatment (6 weeks)

**IMPRIME 1 Peripheral Blood Analyses**

- Overall survival by T cell Activation

**Table 1. mTNBC CPI Monotherapy Trials and IMPRIME 1**


**Table 2. Patient Populations and ORR**

- Estimated from reported median OS, a Javelin Dirix et al., 2018- Pfizer, b PCD4989g Emens et al., 2019- Genentech

**Table 3. mTNBC Patients with Prior Hormone Therapy**

- Data presented in this poster are primary data. IMPRIME1 is ongoing.

**This trial also included a cohort of metastatic melanoma patients post-CPI therapy.**